Technical Analysis for STX - Shield Therapeutics Plc

Grade Last Price % Change Price Change
F 57.0 -0.87% -0.50
STX closed down 5.43 percent on Wednesday, January 27, 2021, on 55 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical STX trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -0.87%
Stochastic Sell Signal Bearish -0.87%
180 Bearish Setup Bearish Swing Setup -0.87%
Multiple of Ten Bearish Other -0.87%
20 DMA Support Bullish -6.25%
Multiple of Ten Bullish Other -6.25%
Weak + Overbought Other -6.25%
Overbought Stochastic Strength -6.25%
Stochastic Reached Overbought Strength -5.63%
Multiple of Ten Bullish Other -5.63%
Older End-of-Day Signals for STX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
1.5x Volume Pace about 4 hours ago
Bearish 180 Entry about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
Down 2% about 4 hours ago
Down 1% about 4 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Shield Therapeutics Plc Description

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Health Iron Pharmaceutical Medicine Clinic Pipe Pharmaceuticals Hospital Disease Clinical Trial Blood Rtt Pharmaceutical Industry Phosphate Clinical Research Kidney Disease Chronic Kidney Disease Anemia Design Of Experiments Inflammatory Bowel Disease

Is STX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 165.0
52 Week Low 39.1
Average Volume 936,096
200-Day Moving Average 103.22
50-Day Moving Average 79.27
20-Day Moving Average 58.47
10-Day Moving Average 58.49
Average True Range 5.75
ADX 42.59
+DI 15.07
-DI 22.81
Chandelier Exit (Long, 3 ATRs ) 47.74
Chandelier Exit (Short, 3 ATRs ) 59.76
Upper Bollinger Band 65.54
Lower Bollinger Band 51.40
Percent B (%b) 0.43
BandWidth 24.20
MACD Line -4.68
MACD Signal Line -6.72
MACD Histogram 2.0368
Fundamentals Value
Market Cap 67.47 Million
Num Shares 117 Million
EPS 3.60
Price-to-Earnings (P/E) Ratio 15.97
Price-to-Sales 19.50
Price-to-Book 4.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 63.50
Resistance 3 (R3) 64.00 62.50 62.50
Resistance 2 (R2) 62.50 60.97 62.25 62.17
Resistance 1 (R1) 60.00 60.03 59.25 59.50 61.83
Pivot Point 58.50 58.50 58.13 58.25 58.50
Support 1 (S1) 56.00 56.97 55.25 55.50 53.17
Support 2 (S2) 54.50 56.03 54.25 52.83
Support 3 (S3) 52.00 54.50 52.50
Support 4 (S4) 51.50